You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Mawi's iSWAB line of biospecimen collection devices include its flagship iSWAB-DNA for the collection of long-fragment double-stranded DNA in buccal cells.
Proteintech said that the combined companies will better address growing challenges in single-cell analysis, super-resolution imaging, and multiplex assays.
The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.
Under the deal, the companies will offer NRGene software for SNP set creation with AgriPlex's genotyping platform and data analysis software.
For the three months ended June 30, the firm reported revenues of $5.4 million, down from $6.3 million in the year-ago quarter and missing the consensus Wall Street estimate of $5.9 million.
The German diagnostics firm expects more than €80 million in 2020 revenues, driven by its recovering core business and its COVID-19 testing business.
Researchers uncovered rare, damaging mutations in genes involved in early brain development among 22 percent of 381 sporadic congenital hydrocephalus cases.
PathogenDx has developed a technology that detects pathogen DNA found on surfaces with applications in agriculture and clinical lab testing.
The agency issued a new draft decision memo, outlining various criteria it intends to apply when determining coverage for current and future blood-based CRC screening tests.
The US Department of Health and Human Services (HHS) said that it would use Fluidigm's saliva-based molecular SARS-CoV-2 test as part of a federal surge testing program.
Thermo Fisher's test is now authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens.
The assay does not require nucleic acid extraction or purification, unlike a LumiraDx SARS-CoV-2 test that received Emergency Use Authorization in August.
DNA Genotek's devices are used with SARS-CoV-2 tests from Clinical Reference Laboratory and P23 Labs, while Clinical Enterprises' kit is offered by Eurofins.
News items for the week of Oct. 12, 2020.
The first stage generated a range of tools and resources for studying the nucleus in time and space including publicly available datasets and software.
Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.
The aggressive subtype, uncovered by a team of researchers in Germany, may also be susceptible to targeted therapy that blocks interferon signaling.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
The researchers analyzed nearly a dozen new samples from various regions of Vanuatu and different eras in combination with previously published samples.
The preventive genomics medicine firm said it will use the funds to strengthen its international expansion efforts and develop new technological capabilities.
The organizations will apply PacBio's HiFi sequencing to a rare disease cohort whose genomes have not yet yielded causal variants by other methods.
Novacyt said that the acquisition secures important intellectual property for its q16 and q32 rapid-PCR instruments for near-patient testing of COVID-19.
MDx revenues grew 67 percent while centralized and POC solutions revenues were down 13 percent, tissue Dx slid 1 percent and diabetes care declined 10 percent.
Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations.
The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.
The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.
The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.
In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.